Molecular therapy for Bone disorders: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 1/January/2017, 11.00 pm

Natural product-derived therapy for tuberculosis: Gingerol, one of the main components of Ginger, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 1/January/2017, 10.57 pm
January 1, 2017
Molecular therapy for triple-negative breast tumors: MiR-29b increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 1/January/2017, 11.11 pm
January 1, 2017
Show all

Introduction: What they say

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.


What we say:

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene


From Research findings to Therapeutic utility

SCYL1-BP1, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. 

price-50[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “SCYL1-BP1 activators or SCYL1-BP1 activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.


Details of the research findings

Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD

Undisclosed mechanistic information: How SCYL1-BP1 suppresses the expression of Tgif2

Amount: $50#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

#Research cooperation

For purchase & payment details, you may reach us at admin@genomediscovery.org


 References:

CitationBoominathan, L., Molecular therapy for Bone disorders: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 1/January/2017, 11.00 pm., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.